Cover Image
Read Now

Teriflunomide (Aubagio) (14 mg film-coated tablet)

The objective of this systematic review is to examine the beneficial and harmful effects of teriflunomide for the treatment of relapsing-remitting form of MS (RRMS)

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa Canadian Agency for Drugs and Technologies in Health 2014, [2014]
Series:Common drug review, clinical review report
Subjects:
Multiple Sclerosis, Relapsing-remitting / Drug Therapy
Crotonates / Adverse Effects
Crotonates / Therapeutic Use
Toluidines / Therapeutic Use
Treatment Outcome
Toluidines / Adverse Effects
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01373nam a2200301 u 4500
001 EB001029783
003 EBX01000000000000000823336
005 00000000000000.0
007 tu|||||||||||||||||||||
008 150411 r ||| eng
245 0 0 |a Teriflunomide (Aubagio) (14 mg film-coated tablet)  |h Elektronische Ressource 
260 |a Ottawa  |b Canadian Agency for Drugs and Technologies in Health  |c 2014, [2014] 
300 |a 1 PDF file (xi, 101 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Multiple Sclerosis, Relapsing-Remitting / drug therapy 
653 |a Crotonates / adverse effects 
653 |a Crotonates / therapeutic use 
653 |a Toluidines / therapeutic use 
653 |a Treatment Outcome 
653 |a Toluidines / adverse effects 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Common drug review, clinical review report 
500 |a Title from PDF caption. - "October 2014." 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK253634  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a The objective of this systematic review is to examine the beneficial and harmful effects of teriflunomide for the treatment of relapsing-remitting form of MS (RRMS) 

Similar Items